The City of Huntsville has taken another step toward bringing pharmaceutical giant Eli Lilly’s $6 billion facility to the ...

History suggests Nvidia should modestly beat Eli Lilly over the next roughly two months,” notes a DataTrek analyst — but ...

VanEck Pharmaceutical ETF is rated a Buy with stability, earnings visibility, and resilience across volatile market cycles.

Very few investors can match Stanley Druckenmiller. He delivered an average annual return of over 30% over three decades at ...

Shares have corrected 55.8 per cent from their high earlier this year of $423.32 to $187.01 based on the Dec. 11 closing ...

It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

The Brown County Community Foundation is pleased to announce the recipient of the 2026 Lilly Endowment Community Scholarship ...

The futures are trading lower after what started as a bounce-back Monday turned into a reversal Monday, as the AI/Datacenter ...

Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Eli Lilly and Company (NYSE: LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on ...